Rep. Michael McCaul Buys Baxter International (BAX) Stock

Rep. Michael McCaul Buys Baxter International (BAX) Stock

Rep. Michael McCaul, a Republican of Texas, disclosed the purchase of $50,001-$100,000 of Baxter International Inc. (NYSE:BAX) stock in a filing made on February 12th, 2026. The transaction, dated January 13th, 2026, was reported officially as made by his spouse.

Michael McCaul's Recent Trades

• 11/28/2025: Bought $1,001 - $15,000 of SAP stock
• 11/26/2025: Sold $15,001 - $50,000 of FCFS stock
• 11/24/2025: Sold $100,001 - $250,000 of G stock
• 11/24/2025: Sold $1,001 - $15,000 of AER stock
• 11/20/2025: Bought $15,001 - $50,000 of MSA stock
• 11/19/2025: Bought $15,001 - $50,000 of ATR stock
• 11/19/2025: Bought $15,001 - $50,000 of VVV stock
• 11/19/2025: Sold $1,001 - $15,000 of GOOGL stock
• 11/19/2025: Sold $50,001 - $100,000 of SSD stock
• 11/19/2025: Sold $1,001 - $15,000 of ASML stock

BAX Stock Performance

Shares of BAX opened at $21.50 on Monday, up 1.12%. The 50-day moving average is $19.97 and the 200-day moving average is $23.81. The 52-week low is $17.40 and the 52-week high is $37.74.

Since the transaction date (January 13th, 2026), BAX shares have risen 6.46%, opening at $20.27 on the transaction date. The stock fell 4.39% in the first week and fell 3.45% over two weeks, and fell 7.70% over one month.

Debt-to-equity was 1.60 and the current ratio was 2.31 with a quick ratio of 1.56. Market capitalization was $11.10 billion and the price-to-earnings ratio was -12.85; beta was 0.59. Return on equity (TTM) was -12.43% and net profit margin (TTM) was -7.68%. Analysts' consensus price target was $19.75 and the analysts' average EPS forecast (2028) was $2.40.

Key Stories Impacting BAX

• (Negative) Baxter reported fourth-quarter 2025 results and a weak 2026 outlook: Q4 revenue beat but adjusted EPS missed and management guided 2026 adjusted EPS of $1.85–$2.05, below Street estimates. (Feb 12, 2026).
• (Negative) The company disclosed continuing problems with its Novum infusion pumps, including multiple voluntary corrections and a Class I FDA classification, representing an ongoing regulatory overhang. (May–Aug 2025; ongoing into 2026).
• (Negative) An FDA early-alert/recall related to Baxter's Spectrum infusion pumps prompted customer return and inspection instructions in February 2025.
• (Neutral) Baxter announced board changes tied to its Q4 results, appointing Michael R. McDonnell to the board while two directors resigned. (Feb 12–13, 2026).
• (Positive) The sale of Baxter's Kidney Care business to Carlyle (renamed Vantive) closed Jan. 31, 2025 for $3.8 billion, and proceeds were used to pay down several billion dollars of debt.
• (Negative) BAX plunged double digits and experienced continued volatile trading after the Feb 12, 2026 earnings print and guidance.

Analyst Ratings for BAX

Goldman Sachs maintained a 'Neutral' rating on 2026-02-17. Barclays maintained an 'Overweight' rating on 2026-02-13 and also maintained 'Overweight' on 2026-01-09. Morgan Stanley maintained an 'Underweight' rating on 2025-12-02. Citigroup maintained a 'Neutral' rating on 2025-10-31.

Presently, 262 analysts have rated BAX with a buy recommendation, 181 have issued a hold, and 15 have given a sell rating. The average rating is 'Hold' with an average price target of $19.75.

Institutional Investors Weigh In On BAX

BLACKROCK, INC. holds 84,783,925 shares worth $1.83 billion. PZENA INVESTMENT MANAGEMENT LLC holds 70,046,251 shares worth $1.51 billion. VANGUARD GROUP INC holds 62,635,136 shares worth $1.35 billion. DODGE & COX holds 56,999,970 shares worth $1.23 billion. FMR LLC holds 34,811,770 shares worth $751.24 million. Currently, 88.61% of the stock is owned by institutional investors.

About Michael McCaul

Representative Michael McCaul is a Republican member of the U.S. House representing Texas's 10th congressional district. He has served in the House since 2005 and was born in 1962; he is 64 years old. His official website is listed as mccaul.house.gov.

About BAX

Baxter International Inc. is a Medical - Instruments & Supplies company that develops and provides a portfolio of healthcare products worldwide, including dialysis therapies, infusion pumps, parenteral nutrition therapies and surgical hemostasis products. The company is headquartered in Deerfield, Illinois; it was incorporated in 1931 and completed its IPO on October 27, 1981. The CEO is Andrew Hider.